Understanding the absorption and bioavailability of Omega-3 fatty acids is essential for optimizing their health benefits. A recent study examined how plasma levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) change after ingesting a single dose of their ethyl ester forms. The findings highlight key differences in how these fatty acids are processed in the body, with EPA showing a higher plasma concentration while DHA may be more readily taken up by tissues. These insights are crucial for improving Omega-3 supplementation strategies, particularly in developing high-bioavailability formulations.
Summary of the Research Report
A recent study, Plasma Levels of EPA and DHA after Ingestion of a Single Dose of EPA and DHA Ethyl Esters (2024), led by Henrieke Marie-Luise Schmieta et al., analyzed the bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters after a single oral dose in healthy male participants.
Key Findings:
- EPA and DHA exist in different forms, including triacylglycerols (TAGs), reconstituted TAGs (rTAGs), and ethyl esters (EEs). The chemical form affects absorption and metabolism.
- Bioavailability is influenced by factors such as formulation, food matrix effects, metabolism, and dosage.
- The study used a cross-over design to measure the absorption and plasma concentration kinetics of 2.2 g EPA and 2.3 g DHA over 72 hours.
- EPA plasma levels increased significantly more than DHA, with a higher peak concentration and a greater area under the curve (AUC).
- DHA may be absorbed and taken up by tissues faster than EPA, particularly by the liver, heart, and brain.
- Single-dose studies provide valuable insights but may not fully reflect long-term availability and effects.
- A separate 10-week study suggested that DHA supplementation leads to a greater increase in the Omega-3 index compared to EPA.
These findings are critical for optimizing Omega-3 supplementation and understanding the physiological roles of EPA and DHA in human health.
Application to MVS Pharma GmbH
At MVS Pharma GmbH, we integrate cutting-edge research into the formulation of our MVS Omega-3 Capsules, ensuring superior bioavailability, oxidation stability, and purity.
1. Bioavailability Optimization
- The study confirms that EPA reaches higher plasma levels faster than DHA, guiding our formulation strategy.
- Instead of ethyl esters, we use rTG form (re-esterified triglycerides), which has higher absorption rates.
- Our marine-derived rTG oil contains 480 mg/g EPA and 320 mg/g DHA, ensuring an optimal balance.
- Total Omega-3 content: Minimum 860 mg/g, including docosapentaenoic acid (DPA), which plays a still-emerging role in health.
- Our oil features 90% triglycerides, significantly higher than the 50%-60% found in standard commercial products.
2. Oxidation Stability
- Omega-3 fatty acids are prone to oxidation, reducing efficacy. To combat this:
- We use IP-certified tocopherols as antioxidants.
- Our fish oil undergoes state-of-the-art stabilization techniques.
- Our product has a 3-year shelf life, compared to the industry standard of 2 years.
Oxidation markers:
- Anisidine Value: 4 (Max: 8)
- Peroxide Value: 0.1 meq/kg (Max: 1.2 meq/kg)
- Total Oxidation (TOTOX) Value: 4 (Max: 10)
3. Pollutant Removal
We ensure stringent purification standards by applying advanced molecular distillation, removing:
- Heavy metals (Arsenic, Cadmium, Lead, Mercury)
- PCBs and dioxins (compliant with TE WHO standards)
We source our Omega-3 from sustainable fisheries, guaranteeing the highest purity.
Scientific Validation
- Our Omega-3 capsules undergo independent laboratory testing, confirming high bioavailability, purity, and safety.
- Research-backed formulation integrates insights from Plasma Levels of EPA and DHA after Ingestion of a Single Dose of EPA and DHA Ethyl Esters (2024).
Conclusion
The study provides essential insights into Omega-3 kinetics, helping us at MVS Pharma GmbH refine our formulations. The rTG form of Omega-3 in our products ensures superior bioavailability compared to ethyl esters (EE).
By focusing on:
- Optimized bioavailability through rTG form
- Superior oxidation stability for enhanced shelf life
- Advanced purification to eliminate pollutants
We provide an industry-leading Omega-3 supplement that maximizes health benefits for our customers.
References
Disclaimer:
As a service to our readers, MVS Pharma GmbH publishing provides access to our library of archived content — in our blog. Please note the date of the last review or update on all articles. No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
MVS Pharma GmbH will soon be launching an omega-3 dietary supplement onto the European market that has been developed for the highest quality standards in terms of oxidation avoidance and therefore greatest bioavailability. In addition, in vitro studies are currently underway at the University of Ulm, in which Professor Dr. Rüdiger Groß tested a patented mouth and nose spray (Virudol) that can eliminate various flu viruses based on natural substances. In addition, MVS has a wholesale license and has specialized in sourcing much-needed medicines such as Amoxicillin, Salbutamol, etc. from India through its local branch with a focus on local quality and safety testing, compliance with international GMP regulations and the highest quality level of user security (examples of local language brochures, identical units of measurement, batch control and full tracking, etc.).
